These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37439069)

  • 1. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.
    Mgodi NM; Murewanhema G; Moyo E; Samba C; Musuka G; Dzinamarira T; Brown JM
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26115. PubMed ID: 37439069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.
    Grimsrud A; Wilkinson L; Delany-Moretlwe S; Ehrenkranz P; Green K; Murenga M; Ngure K; Otwoma NJ; Phanuphak N; Vandevelde W; Vitoria M; Bygrave H
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26095. PubMed ID: 37439076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa.
    Moyo E; Murewanhema G; Musuka G; Dzinamarira T
    Trop Med Infect Dis; 2022 Jul; 7(8):. PubMed ID: 36006246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
    Mohareb AM; Kouamé MG; Nouaman M; Kim AY; Larmarange J; Neilan AM; Lacombe K; Freedberg KA; Boyd A; Coffie P; Hyle EP
    J Int AIDS Soc; 2024 Mar; 27(3):e26218. PubMed ID: 38444112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations.
    Meyer-Rath G; Jamieson L; Pillay Y
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26106. PubMed ID: 37439062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing prevention: Advances in pharmacotherapy for HIV prevention.
    Brizzi M; Sherman EM; Green SB; Nowicki DN; Drwiega EN; Nicol MR; Chastain DB; Sahloff EG; Truong WR; Cluck D; Badowski ME; Michienzi SM; Durham SH
    Pharmacotherapy; 2023 Apr; 43(4):305-320. PubMed ID: 36938645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "These Girls Have a Chance to be the Future Generation of HIV Negative": Experiences of Implementing a PrEP Programme for Adolescent Girls and Young Women in South Africa.
    Duby Z; Bunce B; Fowler C; Jonas K; Bergh K; Govindasamy D; Wagner C; Mathews C
    AIDS Behav; 2023 Jan; 27(1):134-149. PubMed ID: 35793053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.
    Celum C; Grinsztejn B; Ngure K
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26103. PubMed ID: 37439077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
    Bhavaraju N; Shears K; Schwartz K; Mullick S; Jeckonia P; Murungu J; Persaud U; Vij A; Torjesen K
    Curr HIV/AIDS Rep; 2021 Dec; 18(6):508-517. PubMed ID: 34910276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
    Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
    BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.
    Murewanhema G; Malisheni M; Takah NF
    Pan Afr Med J; 2021; 38():308. PubMed ID: 34178226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care.
    Pilgrim N; Jani N; Mathur S; Kahabuka C; Saria V; Makyao N; Apicella L; Pulerwitz J
    PLoS One; 2018; 13(4):e0196280. PubMed ID: 29702659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Service delivery models that promote linkages to PrEP for adolescent girls and young women and men in sub-Saharan Africa: a scoping review.
    Ramraj T; Chirinda W; Jonas K; Govindasamy D; Jama N; McClinton Appollis T; Zani B; Mukumbang FC; Basera W; Hlongwa M; Turawa EB; Mathews C; Nicol E
    BMJ Open; 2023 Mar; 13(3):e061503. PubMed ID: 36972966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PrEP implementation research in Africa: what is new?
    Cowan FM; Delany-Moretlwe S; Sanders EJ; Mugo NR; Guedou FA; Alary M; Behanzin L; Mugurungi O; Bekker LG
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21101. PubMed ID: 27760680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy considerations for scaling up access to HIV pre-exposure prophylaxis for adolescent girls and young women: Examples from Kenya, South Africa, and Uganda.
    Lane J; Brezak A; Patel P; Verani AR; Benech I; Katz A
    Int J Health Plann Manage; 2021 Sep; 36(5):1789-1808. PubMed ID: 34159630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study.
    Mayanja Y; Kamacooko O; Lunkuse JF; Muturi-Kioi V; Buzibye A; Omali D; Chinyenze K; Kuteesa M; Kaleebu P; Price MA
    J Int AIDS Soc; 2022 May; 25(5):e25909. PubMed ID: 35543110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.